申请人:Astellas Pharma Inc.
公开号:EP2154130A1
公开(公告)日:2010-02-17
[Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.
[解决手段]本发明人对一种EP4受体激动剂进行了广泛的研究,结果发现一种新型吡啶酮化合物,其特征在于吡啶酮环的1位被具有酸性基团如羧基的基团取代,6位通过低级烷基、低级亚烷基、醚或硫醚与芳香环基团键合,具有优异的EP4受体激动作用,从而完成了本发明。由于本发明的化合物具有优异的 EP4 受体激动作用和增加大鼠后肢血流量的作用,因此它可用作药物,特别是治疗外周动脉闭塞性疾病的药物。